Clinical trial NCT06494241: Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
Official title: A Multi-Center Study to Evaluate the Guideline Education of Oncology Departments in Small/Middle Tier Cities and County Hospitals for Diagnosis and Treatment Improvement in Patients With Metastatic Non-small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Keywords: Epidermal Growth Factor Receptor
NSCLC
Non-small cell lung cancer
Osbervational
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2024-07-10
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC will be enrolled.

Approximately 1000 patients will be enrolled from about 50 sites in China.

Brief summary: To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.

Detailed description: The primary objective of this study is to assess the implementation of standardized diagnosis and treatment practice in oncology departments of Small/Middle tier cities and County hospitals, after standardized education and implementation of lung cancer clinical practice guidelines for oncology physicians.

Eligibility criteria: Inclusion Criteria:

* Age ≥18 years, at the time of signing the informed consent.
* ECOG performance status 0-2.
* Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC.

Exclusion Criteria:

* Be participating in other intervention clinical trials.
* Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
* Previous enrolment in the other QIP study.

Primary outcomes:
measure: To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP
timeFrame: Follow up approximately 24 months after last patient in
measure: To evaluate the treatment pattern in metastatic NSCLC patients after QIP
timeFrame: Follow up approximately 24 months after last patient in
Secondary outcomes:
measure: To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
timeFrame: Follow up approximately 24 months after last patient in
measure: To evaluate the treatment pattern in metastatic NSCLC patients after QIP
timeFrame: Follow up approximately 24 months after last patient in
measure: To evaluate the treatment pattern in metastatic NSCLC patients after QIP
timeFrame: Follow up approximately 24 months after last patient in
measure: To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
timeFrame: Follow up approximately 24 months after last patient in
measure: To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
timeFrame: Follow up approximately 24 months after last patient in
measure: To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
timeFrame: Follow up approximately 24 months after last patient in
Other outcomes:
measure: To evaluate the molecular testing pattern of physicians
timeFrame: Follow up approximately 24 months after last patient in
measure: To evaluate the treatment pattern of physicians
timeFrame: Follow up approximately 24 months after last patient in
Locations:
city: Anning
country: China
facility: Research Site
city: Anqing
country: China
facility: Research Site
city: Changzhi
country: China
facility: Research Site
city: Daqing
country: China
facility: Research Site
city: Dazhou
country: China
facility: Research Site
city: Dazhu
country: China
facility: Research Site
city: Dingzhou
country: China
facility: Research Site
city: Ganzhou
country: China
facility: Research Site
city: Guang'an
country: China
facility: Research Site
city: Guangzhou
country: China
facility: Research Site
city: Hanzhong
country: China
facility: Research Site
city: Hebi
country: China
facility: Research Site
city: Hengyang
country: China
facility: Research Site
city: Huaibei
country: China
facility: Research Site
city: Jining
country: China
facility: Research Site
city: Jinzhou
country: China
facility: Research Site
city: Liyang
country: China
facility: Research Site
city: Longyan
country: China
facility: Research Site
city: Lu'an
country: China
facility: Research Site
city: Lujiang
country: China
facility: Research Site
city: Meihekou
country: China
facility: Research Site
city: Nanchong
country: China
facility: Research Site
city: Nanyang
country: China
facility: Research Site
city: Ningde
country: China
facility: Research Site
city: Ningxiang
country: China
facility: Research Site
city: Panjin
country: China
facility: Research Site
city: Pingxiang
country: China
facility: Research Site
city: Quanzhou
country: China
facility: Research Site
city: Shengzhou
country: China
facility: Research Site
city: Suzhou
country: China
facility: Research Site
city: Taizhou
country: China
facility: Research Site
city: Tancheng
country: China
facility: Research Site
city: Tongling
country: China
facility: Research Site
city: Wafangdian
country: China
facility: Research Site
city: Weifang
country: China
facility: Research Site
city: Wuzhou
country: China
facility: Research Site
city: Xiangtan
country: China
facility: Research Site
city: Xianning
country: China
facility: Research Site
city: Xiantao
country: China
facility: Research Site
city: Xixian
country: China
facility: Research Site
city: Xuzhou
country: China
facility: Research Site
city: Yangjiang
country: China
facility: Research Site
city: Yangzhou
country: China
facility: Research Site
city: Yibin
country: China
facility: Research Site
city: Yichun
country: China
facility: Research Site
city: Yingkou
country: China
facility: Research Site
city: Zhangjiakou
country: China
facility: Research Site
city: Zhuji
country: China
facility: Research Site
Study officials:
affiliation: Guangdong Provincial People's Hospital
name: Yilong WU
role: PRINCIPAL_INVESTIGATOR
References: